Pro-Dex, Inc. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended September 30, 2023. Pro-Dex designs and manufactures powered surgical instruments, primarily for orthopedic, thoracic, and cranio-maxillofacial markets. Financial amounts below are in thousands of dollars unless stated otherwise.
Financial results
| Metric | Q1 FY2024 | Q1 FY2023 |
|---|---|---|
| Net sales | $11,938 | $11,087 |
| Gross profit / margin | $3,658 / 31% | $2,956 / 27% |
| Operating income | $1,833 | $950 |
| Net income (loss) | $(615) | $1,203 |
| Basic and diluted EPS | $(0.17) | $0.33 |
| Operating cash flow | $392 | $2,892 |
- Sales rose 8%. Repairs increased 79% to $4,023, while medical-device sales were nearly flat at $7,808. Thoracic sales increased to $1,336, offset by lower orthopedic and CMF sales.
- Gross margin improved four percentage points, which management attributed mainly to product mix and lower inventory and warranty charges. Operating expenses fell 9% to $1,825.
- The quarterly net loss was driven primarily by a $2,553 unrealized investment loss, chiefly reflecting the lower estimated value of the Monogram warrant. Operating income improved substantially year over year.
- Cash and cash equivalents were $1,904 at quarter-end, down from $2,936 at June 30, 2023. Working capital was $23,143. Operating cash flow was affected by higher receivables and income-tax assets; financing cash outflow included $1,330 of debt principal payments.
- Notes payable totaled $11,412 ($2,840 current and $8,572 long-term). The company had drawn $1,500 on its $7,000 revolving facility; a separate $3,000 supplemental facility was undrawn. The filing states management believed the company was in compliance with debt covenants, subject to a waiver for the timing of audited fiscal 2023 statements.
Changes, outlook, and notable items
- Compared with the prior-year quarter, the increase in repairs partly reflected the largest customer’s enhanced repair program. Orthopedic sales fell 14%; CMF sales fell 22%; thoracic sales rose 691% following a new product launch. NRE and prototype revenue declined 79%.
- Backlog was approximately $35,700 at September 30, of which $25,400 was scheduled for delivery during the remainder of fiscal 2024. Backlog consists of firm purchase orders and excludes some revenue expected under existing contracts.
- Management expects cash, receivables, and operating cash flows to meet requirements for at least the next 12 months, but noted potential need for debt or equity capital and historical negative operating cash flow when buying long-lead-time materials. Management expects R&D spending to remain relatively flat for the rest of the fiscal year.
- The largest customer’s supply agreement runs through calendar 2025. Customer concentration is significant: one customer represented 70% of quarterly sales, and two customers together represented 93% of quarter-end receivables.
- In October 2023, after quarter-end, Pro-Dex exercised its Monogram warrant for $1,250 in cash and received 1,828,551 Monogram shares, alongside execution of a supply agreement with Monogram.
- The 2022 comparative results were restated for an error in the fair value of the Monogram warrant, increasing reported prior-year quarterly net income by $127 to $1,203.
- Disclosure controls were reported ineffective because of a material weakness involving valuation and disclosure of Level 3 investments. Remediation was ongoing; the company said it had no additional Level 3 investments and believed its September 30 valuation and disclosures were appropriate.
- The filing identifies risks including customer and supplier concentration, product-development and commercialization uncertainty, competition, variable bookings, and possible supply-chain impacts. It reports no material changes to the risk factors in the fiscal 2023 Form 10-K and describes legal proceedings only generally.
Investor verification priorities
- Assess the investment valuation and the effect of Monogram’s post-quarter warrant exercise and supply agreement.
- Monitor customer concentration, repair-program durability, backlog conversion, and the differing trends across product categories.
- Review cash generation, receivables, inventory requirements, debt repayments, revolver availability, and covenant compliance.
- Track remediation of the material weakness in Level 3 investment controls and future reporting of investment fair values.